Editas Medicine Email Format

Biotechnology Research
201-500 employees
Cambridge, MA, USA

Editas Medicine is a clinical-stage biotechnology company pioneering CRISPR genome editing technologies to develop transformative precision medicines for serious genetic diseases worldwide.

Find contacts at Editas Medicine

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@editasmed.com

Company Overview

Industry
Biotechnology Research
Founded
2013
Headquarters
Cambridge, MA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Key Executives
Gilmore O'Neill (President and Chief Executive Officer), Amy Parison (Senior Vice President and Chief Financial Officer), Gregory Whitehead (Executive Vice President and Chief Technical and Quality Officer)

Tech Stack

Adobe Analytics

Analytics

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Editas Medicine?

Editas Medicine uses the first.last format on editasmedicine.com, so Jane Smith would be jane.smith@editasmedicine.com.

What is Editas Medicine's lead in vivo gene editing candidate targeting cardiovascular disease?

Editas Medicine's lead in vivo candidate is EDIT-401, an experimental CRISPR-based medicine designed to reduce LDL cholesterol by editing the LDLR gene. Preclinical studies in non-human primates showed greater than 90% mean LDL-C reduction from a single dose.

Who leads Editas Medicine as CEO?

Gilmore O'Neill has served as President and Chief Executive Officer of Editas Medicine since June 2022. He previously served as Executive Vice President of R&D and Chief Medical Officer at Sarepta Therapeutics and held senior roles at Biogen.

How did Editas Medicine's RUBY trial evaluate reni-cel for sickle cell disease?

The RUBY trial was a Phase 1/2/3 multi-center study that assessed reni-cel, an AsCas12a gene-edited cell medicine, in patients with severe sickle cell disease. Clinical data showed early and sustained increases in total hemoglobin and fetal hemoglobin levels across enrolled patients.

Can Clay help me find verified Editas Medicine contact emails for outreach?

Yes, Clay can help you find and verify employee email addresses at Editas Medicine by applying the confirmed first.last@editasmedicine.com format and cross-referencing multiple data sources, making it straightforward to build an accurate prospect list for outreach.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles